SOUTH SAN FRANCISCO, Calif. — Zenflow, Inc. today announced the first commercial procedures with the Zenflow Spring® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as enlarged prostate. The first procedure, performed by Sijo Parekattil, MD, FACS, Founder and President of Avant Concierge Urology, took place on July 29, 2026 in his office in Winter Garden, Florida.
Approved for use by the U.S. Food and Drug Administration (FDA) in December 2025, the Zenflow Spring is a novel, first-line interventional therapy (FIT) that offers the more than 30 million U.S. men living with BPH a minimally invasive treatment option with proven long-term durability and unique safety advantages -- including no need for post-procedure catheterization, and the ability to reverse treatment if desired.